BeOne Medicines Unveils ESMO Data and Targets HCC Registration in 2026

BeOne Medicines presented updated and early clinical data across HCC and NSCLC and plans to start global registrational trials for its GPC3×4-1BB bispecific in late-line HCC by end-2026. Its CEA-targeting ADC received FDA Fast Track in October 2026.